BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37364599)

  • 1. Clinical and prognostic features of Langerhans cell histiocytosis in adults.
    Sato A; Kobayashi M; Yusa N; Ogawa M; Shimizu E; Kawamata T; Yokoyama K; Ota Y; Ichinohe T; Ohno H; Mori Y; Sakaida E; Kondo T; Imoto S; Nannya Y; Mitani K; Tojo A
    Cancer Sci; 2023 Sep; 114(9):3687-3697. PubMed ID: 37364599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
    Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
    Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between clinicopathologic characteristics and BRAF
    Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ
    Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating cell-free BRAF
    Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
    Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pathophysiology and treatment of adult Langerhans cell histiocytosis].
    Tojo A; Kobayashi M
    Rinsho Ketsueki; 2020; 61(9):1028-1034. PubMed ID: 33162496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Langerhans cell histiocytosis in adults: Advances in pathophysiology and treatment.
    Kobayashi M; Tojo A
    Cancer Sci; 2018 Dec; 109(12):3707-3713. PubMed ID: 30281871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Langerhans cell histiocytosis in adolescent patients: a single-centre retrospective study.
    Cai HC; Chen J; Liu T; Cai H; Duan MH; Li J; Zhou DB; Cao XX
    Orphanet J Rare Dis; 2022 Jul; 17(1):268. PubMed ID: 35841042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis.
    Cao XX; Duan MH; Zhao AL; Cai H; Chen J; Gao XM; Liu T; Cai HC; Zhang L; Sun J; Liang ZY; Zhou DB; Li J
    Am J Hematol; 2022 Feb; 97(2):203-208. PubMed ID: 34797941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features and outcomes of adult Langerhans cell histiocytosis: a single-center experience.
    Kobayashi M; Ando S; Kawamata T; Makiyama J; Yokoyama K; Imai Y; Tojo A
    Int J Hematol; 2020 Aug; 112(2):185-192. PubMed ID: 32514929
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Ozer E; Sevinc A; Ince D; Yuzuguldu R; Olgun N
    Pediatr Dev Pathol; 2019 Oct; 22(5):449-455. PubMed ID: 31072207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [BRAF-V600E mutation and its clinical significance in children with Langerhans cell histiocytosis].
    Tang X; Guo X; Sun LY; Ai Y; Yang X; Sun JJ; Wu JR; Gao J
    Zhongguo Dang Dai Er Ke Za Zhi; 2018 Apr; 20(4):290-294. PubMed ID: 29658453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adult-onset Langerhans cell histiocytosis of bone: A case series highlighting a rare entity.
    Javadi T; Hill C; McLemore ML; Oskouei S; Bahrami A
    Ann Diagn Pathol; 2023 Oct; 66():152171. PubMed ID: 37295039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.
    Evseev D; Kalinina I; Raykina E; Osipova D; Abashidze Z; Ignatova A; Mitrofanova A; Maschan A; Novichkova G; Maschan M
    Int J Hematol; 2021 Dec; 114(6):725-734. PubMed ID: 34383272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
    Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
    J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.
    Novosad O; Skrypets T; Pastushenko Y; Titorenko I; Martynchyk A; Skachkova O; Inomistova M; Gorbach A; Khranovska N; Kryachok I
    Klin Onkol; 2018; 31(2):130-136. PubMed ID: 29708356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Langerhans Cell Histiocytosis Associated With Renal Cell Carcinoma Is a Neoplastic Process: Clinicopathologic and Molecular Study of 7 Cases.
    Agaimy A; Bonert M; Naqvi A; Wang C; Trpkov K; Dettmar P; Wintzer HO; Stoehr R; Hes O; Williamson SR; Gibson IW; Hartmann A
    Am J Surg Pathol; 2020 Dec; 44(12):1658-1665. PubMed ID: 32910018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress towards molecular-based management of childhood Langerhans cell histiocytosis.
    Héritier S; Emile JF; Hélias-Rodzewicz Z; Donadieu J
    Arch Pediatr; 2019 Jul; 26(5):301-307. PubMed ID: 31281037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the BRAFV600E mutation in 19 cases of Langerhans cell histiocytosis in Japan.
    Sasaki Y; Guo Y; Arakawa F; Miyoshi H; Yoshida N; Koga Y; Nakashima K; Kurita D; Niino D; Seto M; Ohshima K
    Hematol Oncol; 2017 Sep; 35(3):329-334. PubMed ID: 27041734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Langerhans cell histiocytosis.
    Rodriguez-Galindo C; Allen CE
    Blood; 2020 Apr; 135(16):1319-1331. PubMed ID: 32106306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apparent Lack of
    Kemps PG; Zondag TC; Steenwijk EC; Andriessen Q; Borst J; Vloemans S; Roelen DL; Voortman LM; Verdijk RM; van Noesel CJM; Cleven AHG; Hawkins C; Lang V; de Ru AH; Janssen GMC; Haasnoot GW; Franken KLMC; van Eijk R; Solleveld-Westerink N; van Wezel T; Egeler RM; Beishuizen A; van Laar JAM; Abla O; van den Bos C; van Veelen PA; van Halteren AGS
    Front Immunol; 2019; 10():3045. PubMed ID: 31998317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.